Clinical Cancer Research, Vol 2, Issue 11 1859-1865, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer

T Nishimura, K Newkirk, RB Sessions, PA Andrews, BJ Trock, AA Rasmussen, EA Montgomery, EK Bischoff and KJ Cullen
Department of Otolaryngology, Kanazawa University, Kanazawa, Ishikawa 920, Japan.

The glutathione S-transferases (GSTs) play an important role in the cell's defense against toxic substances. The GSTs are a family of enzymes produced by several genes that interact with distinct but overlapping substrates and that may play a role in resistance of tumor cells to several chemotherapeutic agents. We examined the correlation between expression of GSTs determined by immunohistochemistry and clinical response to platinum-based chemotherapy in 51 patients with head and neck cancer, who received a total of 56 courses of chemotherapy. The overall response rate for the 56 chemotherapy treatment courses was 48%. The overall response rate (complete response + partial response) for patients with low GST scores was 88% (21 of 24), whereas among the patients with high GST scores, the overall response rate was 19% (6 of 32; P = 0.001). Patients with a low GST score were 4.7 times more likely to respond to chemotherapy than patients with high GST scores. GST scores corresponded to response in 84% of cases. Among 23 patients treated with neoadjuvant chemotherapy, the overall response rate for patients with low GST scores was 100% (14 of 14), whereas among the patients with high GST scores, the overall response rate was 44% (4 of 9; P = 0.002). Among 33 patients treated with chemotherapy for relapsed disease, the overall response rate for patients with low GST scores was 70% (7 of 10), whereas among the patients with high GST scores, the overall response rate was 8.6% (2 of 23; P < 0.001). We conclude that GST expression correlates well with response to platinum-based chemotherapy in head and neck cancer.

This article has been cited by other articles:

				L. Schumaker, N. Nikitakis, O. Goloubeva, M. Tan, R. Taylor, and K. J. Cullen Elevated Expression of Glutathione S-Transferase {pi} and p53 Confers Poor Prognosis in Head and Neck Cancer Patients Treated with Chemoradiotherapy but not Radiotherapy Alone Clin. Cancer Res., September 15, 2008; 14(18): 5877 - 5883. [Abstract] [Full Text] [PDF]

				N. Boku, A. Ohtsu, S. Yoshida, K. Shirao, Y. Shimada, I. Hyodo, H. Saito, Y. Miyata, and Gastrointestinal Oncology Study Group of Japan Cli Significance of Biological Markers for Predicting Prognosis and Selecting Chemotherapy Regimens of Advanced Gastric Cancer Patients between Continuous Infusion of 5-FU and a Combination of 5-FU and Cisplatin Jpn. J. Clin. Oncol., May 23, 2007; (2007) hym015v1. [Abstract] [Full Text] [PDF]

				H-C Kwon, M. Roh, S. Oh, S-H Kim, M. Kim, J-S Kim, and H-J Kim Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer Ann. Onc., March 1, 2007; 18(3): 504 - 509. [Abstract] [Full Text] [PDF]

				A. Loercher, T. L. Lee, J. L. Ricker, A. Howard, J. Geoghegen, Z. Chen, J. B. Sunwoo, R. Sitcheran, E. Y. Chuang, J. B. Mitchell, et al. Nuclear Factor-{kappa}B is an Important Modulator of the Altered Gene Expression Profile and Malignant Phenotype in Squamous Cell Carcinoma Cancer Res., September 15, 2004; 64(18): 6511 - 6523. [Abstract] [Full Text] [PDF]

				K. J. Cullen, K. A. Newkirk, L. M. Schumaker, N. Aldosari, J. D. Rone, and B. R. Haddad Glutathione S-Transferase {pi} Amplification is Associated with Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines and Primary Tumors Cancer Res., December 1, 2003; 63(23): 8097 - 8102. [Abstract] [Full Text] [PDF]

				C. M. Rudin, Z. Yang, L. M. Schumaker, D. J. VanderWeele, K. Newkirk, M. J. Egorin, E. G. Zuhowski, and K. J. Cullen Inhibition of Glutathione Synthesis Reverses Bcl-2-mediated Cisplatin Resistance Cancer Res., January 15, 2003; 63(2): 312 - 318. [Abstract] [Full Text] [PDF]

				D. M. Townsend, M. Deng, L. Zhang, M. G. Lapus, and M. H. Hanigan Metabolism of Cisplatin to a Nephrotoxin in Proximal Tubule Cells J. Am. Soc. Nephrol., January 1, 2003; 14(1): 1 - 10. [Abstract] [Full Text] [PDF]

				J. Stoehlmacher, D. J. Park, W. Zhang, S. Groshen, D. D. Tsao-Wei, M. C. Yu, and H.-J. Lenz Association Between Glutathione S-Transferase P1, T1, and M1 Genetic Polymorphism and Survival of Patients With Metastatic Colorectal Cancer J Natl Cancer Inst, June 19, 2002; 94(12): 936 - 942. [Abstract] [Full Text] [PDF]

				A. Fortin, C. Couture, R. Doucet, M. Albert, J. Allard, and B. Tetu Does Histologic Grade Have a Role in the Management of Head and Neck Cancers? J. Clin. Oncol., November 1, 2001; 19(21): 4107 - 4116. [Abstract] [Full Text] [PDF]

				G. Dong, E. Loukinova, Z. Chen, L. Gangi, T. I. Chanturita, E. T. Liu, and C. Van Waes Molecular Profiling of Transformed and Metastatic Murine Squamous Carcinoma Cells by Differential Display and cDNA Microarray Reveals Altered Expression of Multiple Genes Related to Growth, Apoptosis, Angiogenesis, and the NF-{{kappa}}B Signal Pathway Cancer Res., June 1, 2001; 61(12): 4797 - 4808. [Abstract] [Full Text] [PDF]

				H. Shiga, E. I. Heath, A. A. Rasmussen, B. Trock, P. G. Johnston, A. A. Forastiere, M. Langmacher, A. Baylor, M. Lee, and K. J. Cullen Prognostic Value of p53, Glutathione S-Transferase {{pi}}, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer Clin. Cancer Res., December 1, 1999; 5(12): 4097 - 4104. [Abstract] [Full Text] [PDF]